Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Harrison Farber (Boston, United States of America), Harrison Farber, Dennis Busse, Janethe de Oliveira Pena, Hossein-Ardeschir Ghofrani. Riociguat in chronic thromboembolic pulmonary hypertension (CTEPH): ERS/ESC risk assessment in CHEST. Eur Respir J 2016; 48: Suppl. 60, 3598

Member's Comments

No comment yet.

Related content which might interest you: Riociguat in pulmonary arterial hypertension: ERS/ESC risk assessment in PATENT Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Thrombophilic risk factors for chronic thromboembolic pulmonary hypertension (CTEPH) in Korea Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 Chronic thromboembolic pulmonary hypertension (CTEPH) Source: Respipedia Article Year: 2018 Chronic thromboembolic pulmonary hypertension (CTEPH) and beyond Source: Annual Congress 2011 - Ceremony for Pulmonary Arterial Hypertension Award (supported by Actelion) followed by Pulmonary Hypertension in the Clinic Grand Round - an interactive session Year: 2011 Management of chronic thromboembolic pulmonary hypertension (CTEPH): A physician-based perception study Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – ME5 Chronic thromboembolic pulmonary hypertension Year: 2015 Chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – State of the art session: Pulmonary vascular diseases Year: 2018 Chronic thromboembolic pulmonary hypertension Source: International Congress 2017 – Russian Programme 2017 Year: 2017 Chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (1) 1801915; 10.1183/13993003.01915-2018 Year: 2019 Prevalence of relapses and chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE) Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 ERS statement on chronic thromboembolic pulmonary hypertension Source: ERS webinar 2021: ERS statement on chronic thromboembolic pulmonary hypertension Year: 2021 Incidence and outcomes of haemoptysis in patients with operable and non-operable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: International Congress 2016 – Pulmonary hypertension and chronic thromboembolic pulmonary hypertension Year: 2016 Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: Eur Respir J, 53 (6) 1802004; 10.1183/13993003.02004-2018 Year: 2019 Risk factors for chronic thromboembolic pulmonary hypertension Source: Eur Respir Rev 2012; 21: 27-31 Year: 2012 Challenging cases in PH Source: Eur Respir Rev 2008; 17: 19-23 Year: 2007 Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology Source: Eur Respir Rev 2009; 19: 59-63 Year: 2010 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Riociguat for the treatment of pulmonary hypertension: Safety data from the EXPERT registry Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016